• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.52% Nasdaq Down0.25%

    Celladon Corporation (CLDN)

    -NasdaqGM
    1.20 0.00(0.00%) Aug 3, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Celladon Corporation
    11988 El Camino Real
    Suite 650
    San Diego, CA 92130
    United States - Map
    Phone: 858-366-4288
    Fax: 858-964-0974
    Website: http://www.celladon.net

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:34

    Business Summary 

    Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure. The company is also developing membrane-bound form of Stem Cell Factor for the treatment of cardiac ischemic damage; and compounds for the treatment of diabetes and neurodegenerative diseases. Celladon Corporation was founded in 2000 and is headquartered in San Diego, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Celladon Corporation

    Key Executives 
     PayExercised
    Mr. Paul B. Cleveland J.D., 58
    Chief Exec. Officer and Director
    308.00K0.00
    Ms. Elizabeth E. Reed J.D., 44
    VP, Gen. Counsel and Sec.
    328.00K0.00
    Dr. Roger J. Hajjar Ph.D., M.D., 49
    Co-Founder and Scientific Advisor
    N/AN/A
    Mr. Andrew C. Jackson , 46
    Chief Financial Officer and Corp. Controller
    N/AN/A
    Mr. Fredrik Wiklund , 44
    VP of Corp. Devel. & Investor Relations
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders